Origami Therapeutics
Origami Therapeutics is a preclinical-stage biotech developing small-molecule protein degraders and conformation correctors for neurodegenerative diseases such as Huntington's, using its proprietary ORICISION™ platform and patient-derived disease models, and partnering with larger pharmaceutical companies for late-stage development and commercialization.
- Company typePrivate
- Founded2016
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Origami Therapeutics does
Origami Therapeutics is a preclinical-stage biotechnology company founded in 2016 by Dr. Beth Hoffman and headquartered in San Diego, California. The company develops small molecule protein degraders and protein conformation correctors targeting the root genetic causes of neurodegenerative diseases, including Huntington's disease (lead program ORI-003), Alzheimer's, Parkinson's, ALS, and Frontotemporal Dementia. Its work is built around the proprietary ORICISION™ Drug Discovery Platform, which combines patient-derived pluripotent stem cell models (including 3D spheroid brain cell cultures containing neurons and glia) with medicinal chemistry and machine learning–driven compound optimization to match the right therapeutic modality (degradation vs. correction) to each disease.
The company's underlying hypothesis is that targeting toxic misfolded proteins via the autophagy-lysosome pathway can address indications where no disease-modifying therapies exist. Its degraders are designed to selectively eliminate disease-causing protein species while sparing normal forms, with weak-binding requirements that allow it to address roughly 80% of the proteome traditionally considered "undruggable." Conformation correctors stabilize proper protein folding, addressing upstream pathology rather than symptoms. These are oral small molecules intended to cross the blood-brain barrier.
Origami is pre-revenue and does not sell commercial products. Its revenue model is licensing- and milestone-driven: it advances candidates through preclinical and early clinical stages and then partners with larger pharmaceutical companies for late-stage development and commercialization. The execution of this model is evidenced by the January 2026 global collaboration and option agreement with Ipsen for a protein degrader program in a rare inherited neurodegenerative disorder, under which Origami is eligible for upfront, development, regulatory, and commercial milestone payments plus royalties, with Ipsen assuming global development responsibility upon option exercise. The company is approximately 18 months from entering clinical trials.
Origami Therapeutics firmographics
Firmographics- Name
- Origami Therapeutics
- Legal name
- Origami Therapeutics, Inc.
- Website
- https://origamitherapeutics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Origami Therapeutics is a preclinical-stage biotech developing small-molecule protein degraders and conformation correctors for neurodegenerative diseases such as Huntington's, using its proprietary ORICISION™ platform and patient-derived disease models, and partnering with larger pharmaceutical companies for late-stage development and commercialization.
- Ownership category
- akta.pro rank
Origami Therapeutics industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Origami Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Origami Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing and Milestone Payments: Origami receives undisclosed upfront payments plus potential milestone payments and royalties tied to development and regulatory achievements under licensing agreements with pharmaceutical partners like Ipsen.
- Collaboration Research Funding: Funding received for research collaboration activities under option and collaboration agreements, with payments aligned to pre-agreed development, regulatory and commercial milestones.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Origami Therapeutics product offering
Product offeringCore offering
Origami Therapeutics is a preclinical-stage biotechnology company developing small-molecule protein degraders and protein conformation correctors for neurodegenerative diseases. Its proprietary ORICISION™ Drug Discovery Platform leverages patient-derived disease models, spheroid brain cell cultures, and machine learning to design oral small-molecule therapeutics that selectively degrade disease-causing proteins or correct misfolded protein conformations. Lead program ORI-003 is being advanced in Huntington's disease, with the company pursuing licensing and option-to-license partnerships with larger pharmaceutical firms for late-stage development and commercialization.
Product overview
Origami Therapeutics is developing an integrated portfolio of protein degradation and correction therapies built around its proprietary ORICISION™ technology platform. The platform enables discovery of both protein degraders and conformation correctors, with the lead program ORI-003 targeting Huntington's disease. The company applies precision medicine approaches using patient-derived disease models to ensure successful clinical translation.
Differentiator
Problem solved
Functional benefit
Products and services
- ORICISION™ Drug Discovery Platform
Quantifiable outcome
- Ability to address ~80% of proteome currently considered 'undruggable' through weak binding requirements
- +1 more outcomes
Companies that use Origami Therapeutics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Origami Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
Origami Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- IpsencoreOrigami Therapeutics entered a global collaboration and option agreement with Ipsen to develop a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder. Under the terms, Ipsen obtains an exclusive option to license the program globally following successful drug candidate nomination. Upon exercise of the option, Ipsen assumes responsibility for global development and commercialization. Origami is eligible to receive upfront, development, regulatory, and commercial milestone payments plus potential royalties.
- o2hminorOrigami Therapeutics was highlighted by o2h as one of their Kick Starter Program success stories. The o2h Kickstarter program supports innovative biotech startups at crucial moments in their drug discovery journey.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Origami Therapeutics competitors and assessment
Company assessmentDirect peers
- Arvinas: Arvinas is a clinical-stage biotech pioneer in targeted protein degradation (PROTAC platform), most directly comparable to Origami in using small-molecule degraders to remove disease-causing proteins, including CNS-penetrant programs.
- Kymera Therapeutics: Kymera is a clinical-stage protein degrader company developing small-molecule heterobifunctional degraders with programs across immunology and oncology, the most direct mechanistic comparator to Origami's degrader approach.
- Nurix Therapeutics: Nurix is a clinical-stage targeted protein degradation company developing small-molecule degraders with active pharma partnerships, comparable to Origami in degrader modality and BD-driven business model.
- C4 Therapeutics: C4 Therapeutics develops small-molecule protein degraders (TORPEDO platform) and pursues pharma partnerships, sharing Origami's core modality and partnership-led commercialization strategy.
- Monte Rosa Therapeutics: Monte Rosa is a clinical-stage biotech developing small-molecule glue-based protein degraders, a closely adjacent degrader modality to Origami's approach and comparable in stage and therapeutic-area breadth.
Broad incumbents
- Denali Therapeutics: Denali is a clinical-stage biotech developing therapeutics for neurodegenerative diseases with BBB-penetrant platforms, broadly comparable to Origami in CNS focus but with broader modality and clinical-stage resources.
- BioMarin Pharmaceutical: BioMarin is an established rare-disease biopharma active in neurological/rare disorders and serves as the partner-type counterpart to Ipsen that Origami is engaging with for development and commercialization.
Emerging players
- Voyager Therapeutics: Voyager is a clinical-stage gene therapy company focused on CNS/neurodegenerative diseases, comparable to Origami in CNS therapeutic focus and partnership-driven model, though different in modality.
- CASI Pharmaceuticals / Sage Therapeutics peer set: Sage Therapeutics (a Biogen subsidiary) develops CNS therapeutics for neurological disorders, an adjacent peer in neurodegenerative/CNS focus though operating at later stage with a different target-based approach.
- Plexium: Plexium is an early-stage targeted protein degradation company using a cell-permeable molecular glue-based platform, comparable to Origami in degrader modality and preclinical-to-IND stage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Origami Therapeutics social profiles
Digital presenceOrigami Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Origami Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Origami Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Origami Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Origami Therapeutics
What does Origami Therapeutics do?
Origami Therapeutics is a preclinical-stage biotechnology company developing small-molecule protein degraders and protein conformation correctors for neurodegenerative diseases. Its proprietary ORICISION™ Drug Discovery Platform leverages patient-derived disease models, spheroid brain cell cultures, and machine learning to design oral small-molecule therapeutics that selectively degrade disease-causing proteins or correct misfolded protein conformations. Lead program ORI-003 is being advanced in Huntington's disease, with the company pursuing licensing and option-to-license partnerships with larger pharmaceutical firms for late-stage development and commercialization.
Is Origami Therapeutics a public or private company?
Origami Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Origami Therapeutics founded?
Origami Therapeutics was founded in 2016. It employs 1 to 10 people.
Where is Origami Therapeutics based?
Origami Therapeutics is headquartered in San Diego, United States, in the North America region.
How does Origami Therapeutics make money?
Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are collaboration Research Funding.
Who are Origami Therapeutics's main competitors?
Direct peers on record are Arvinas, Kymera Therapeutics, Nurix Therapeutics, C4 Therapeutics and Monte Rosa Therapeutics. Broad incumbents are Denali Therapeutics and BioMarin Pharmaceutical. Emerging players are Voyager Therapeutics, CASI Pharmaceuticals / Sage Therapeutics peer set and Plexium.
Does Origami Therapeutics have an API?
No public API is recorded for Origami Therapeutics.
What industry is Origami Therapeutics in?
Origami Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.